We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+18.11%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.07B
AUM Growth
+$214M
Cap. Flow
+$110M
Cap. Flow %
10.26%
Top 10 Hldgs %
29.29%
Holding
121
New
28
Increased
49
Reduced
15
Closed
16

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$25.5M
2
RDUS
Radius Health, Inc.
RDUS
+$18M
3
LLY icon
Eli Lilly
LLY
+$16.4M
4
BHC icon
Bausch Health
BHC
+$16.3M
5
TMO icon
Thermo Fisher Scientific
TMO
+$12.9M

Top Sells

Rank Stock Value
1
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$30.2M
2
MRK icon
Merck
MRK
+$25.6M
3
STJ
St Jude Medical
STJ
+$21.8M
4
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$18.6M
5
HRC
HILL-ROM HOLDINGS, INC.
HRC
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 75.22%
2 Financials 1.56%
3 Industrials 0.97%
4 Technology 0.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JUNO
51
DELISTED
Juno Therapeutics, Inc.
JUNO
$7.43M 0.69%
122,426
-22,000
-15% -$1.07M
RLYP
52
DELISTED
RELYPSA INC COM
RLYP
$7.39M 0.69%
205,000
+17,000
+9% +$613K
DVA icon
53
DaVita
DVA
$11.7B
$7.32M 0.68%
+90,000
New +$6.91M
ADXS
54
DELISTED
Advaxis Inc
ADXS
$7.08M 0.66%
32,667
+17,667
+118% +$2.72M
ZSPH
55
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
$6.65M 0.62%
158,000
+51,000
+48% +$2.33M
WX
56
DELISTED
WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS
WX
$6.51M 0.61%
168,000
+60,500
+56% +$2.33M
TBPH icon
57
Theravance Biopharma
TBPH
$877M
$6.49M 0.61%
374,000
+84,000
+29% +$1.54M
GWPH
58
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$6.38M 0.6%
70,000
+42,000
+150% +$3.41M
CNXR
59
DELISTED
Connecture, Inc.
CNXR
$6.21M 0.58%
600,000
+45,775
+8% +$423K
STE icon
60
Steris
STE
$23.1B
$6.18M 0.58%
88,000
+7,000
+9% +$462K
CHRS icon
61
Coherus Oncology
CHRS
$196M
$6.09M 0.57%
199,051
-41,000
-17% -$1.06M
NVAX icon
62
Novavax
NVAX
$1.31B
$6.04M 0.56%
36,500
+4,750
+15% +$771K
TNDM icon
63
Tandem Diabetes Care
TNDM
$1.56B
$6M 0.56%
47,580
+12,580
+36% +$1.64M
ACHN
64
DELISTED
Achillion Pharmaceuticals
ACHN
$5.92M 0.55%
600,000
+235,000
+64% +$2.93M
KYTH
65
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$5.77M 0.54%
+115,000
New +$4.83M
EPZM
66
DELISTED
Epizyme, Inc
EPZM
$5.76M 0.54%
306,500
+125,000
+69% +$2.58M
PBYI icon
67
Puma Biotechnology
PBYI
$454M
$5.73M 0.54%
24,250
+1,000
+4% +$214K
RARE icon
68
Ultragenyx Pharmaceutical
RARE
$2.55B
$5.71M 0.53%
92,000
+21,000
+30% +$1.17M
WCG
69
DELISTED
Wellcare Health Plans, Inc.
WCG
$5.49M 0.51%
60,000
– –
CORV
70
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$5.23M 0.49%
+565,000
New +$5.41M
ACT.PRA
71
DELISTED
ACTAVIS PLC Pfd Conv Ser A (Irl)
ACT.PRA
$5.15M 0.48%
+5,000
New +$5.23M
DARE icon
72
Dare Bioscience
DARE
$21M
$4.87M 0.46%
4,500
-83
-2% -$80.3K
KYNB
73
Kyntra Bio
KYNB
$29.4M
$4.75M 0.44%
6,052
– –
AERI
74
DELISTED
Aerie Pharmaceuticals
AERI
$4.58M 0.43%
146,000
+6,000
+4% +$174K
REGN icon
75
Regeneron Pharmaceuticals
REGN
$80.8B
$4.51M 0.42%
10,000
+1,000
+11% +$424K
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2015 Portfolio in Review

As of Q1 2015, Rock Springs Capital Management held 121 positions worth $1.07B, up 25% from $855M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management deployed $110M of net new capital in Q1 2015, opening 28 new positions and adding to 49 existing holdings. Its largest new stake was Pfizer: 801,040 shares worth $26.4M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 73% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Avadel Pharmaceuticals, an estimated $3.37M trimmed.

  • Rock Springs Capital Management's largest Q1 2015 buy was Pfizer: 801,040 shares worth $26.4M.
  • Rock Springs Capital Management added most to Bausch Health in Q1 2015, an estimated $16.3M increase.
  • Rock Springs Capital Management's biggest Q1 2015 reduction was Avadel Pharmaceuticals, cutting an estimated $3.37M.
  • Rock Springs Capital Management fully exited COVIDIEN PLC COM SHS NEW (IRELAND) in Q1 2015, selling an estimated $30.2M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $1.07B portfolio in Q1 2015.
  • Rock Springs Capital Management opened 28 new positions and closed 16 in Q1 2015.
  • Rock Springs Capital Management's portfolio value rose 25% quarter-over-quarter to $1.07B.

Based on Rock Springs Capital Management's 13F filing for Q1 2015, filed 15 May 2015.